Here, we investigated the effects of anti-PD-1, anti-PD-L1 and anti-CTLA-4 immunomodulatory mAbs on different tumor cells by choosing in particular breast and lung cell lines, as many ongoing clinical trials are evaluating the efficacy of immunomodulatory mAbs on these tumors [32,33,34]. The gene discussed is CD274; the disease is neoplasm.